Cargando…

Rapid literature review: definition and methodology

Introduction: A rapid literature review (RLR) is an alternative to systematic literature review (SLR) that can speed up the analysis of newly published data. The objective was to identify and summarize available information regarding different approaches to defining RLR and the methodology applied t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smela, Beata, Toumi, Mondher, Świerk, Karolina, Francois, Clement, Biernikiewicz, Małgorzata, Clay, Emilie, Boyer, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392303/ https://www.ncbi.nlm.nih.gov/pubmed/37533549 http://dx.doi.org/10.1080/20016689.2023.2241234

Ejemplares similares

Systematic literature reviews over the years
por: Smela, Beata, et al.
Publicado: (2023)

Characteristics of doctor-shoppers: a systematic literature review
por: Biernikiewicz, Małgorzata, et al.
Publicado: (2019)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

A critical analysis and review of Lancet COVID-19 hydroxychloroquine study
por: Toumi, Mondher, et al.
Publicado: (2020)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Gene therapy randomised clinical trials in Europe – a review paper of methodology and design
por: Ilieva, Krassimira, et al.
Publicado: (2020)

Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries
por: Clay, Emilie, et al.
Publicado: (2012)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review
por: Azaiez, Chiraz, et al.
Publicado: (2018)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
por: Dabbous, Monique, et al.
Publicado: (2019)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update
por: Han, Ru, et al.
Publicado: (2019)

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study
por: Clay, Emilie, et al.
Publicado: (2019)

Novel methodology for pharmaceutical expenditure forecast
por: Vataire, Anne-Lise, et al.
Publicado: (2014)

Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe
por: Monleón, Clara, et al.
Publicado: (2022)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D
por: Dorey, Julie, et al.
Publicado: (2016)

From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses
por: Thokagevistk, Katia, et al.
Publicado: (2019)

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC
por: Siani, Carole, et al.
Publicado: (2015)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013)

Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
por: Dabbous, Omar, et al.
Publicado: (2022)

Benefits of probabilistic sensitivity analysis – a review of NICE decisions
por: Adalsteinsson, Erpur, et al.
Publicado: (2013)

Why “American Patients First” is likely to raise drug prices outside of the United States
por: Dabbous, Monique, et al.
Publicado: (2019)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis
por: Millier, Aurelie, et al.
Publicado: (2011)

Health economic evaluation of gene replacement therapies: methodological issues and recommendations
por: Aballéa, Samuel, et al.
Publicado: (2020)

The Market Access Society launches a new journal
por: Toumi, Mondher
Publicado: (2013)

Measuring the health-related quality of life in young children: how far have we come?
por: Germain, Nicola, et al.
Publicado: (2019)

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
por: Moćko, Paweł, et al.
Publicado: (2016)

Definition of the Mediterranean Diet: A Literature Review
por: Davis, Courtney, et al.
Publicado: (2015)

Toward a Literature-Driven Definition of Big Data in Healthcare
por: Baro, Emilie, et al.
Publicado: (2015)

Diagnosis of hypogonadism in patients treated with low energy shock wave therapy for erectile dysfunction: a narrative review
por: Kałka, Dariusz, et al.
Publicado: (2020)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Mapping definitions, measures and methodologies of assessing police violence in the health literature: a scoping review protocol
por: Harris, Latesha K, et al.
Publicado: (2023)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
por: Dahmani, Hajer, et al.
Publicado: (2023)

Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram
por: Llorca, Pierre-Michel, et al.
Publicado: (2015)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4ncbrflp11v5q7pjngnb6reaui